ABSTRACT
Background: Type 2 diabetes mellitus (T2DM) is one of the most common non-communicable diseases associated with ‘atherogenic dyslipidemia’ The treatment of T2DM often is initiated with oral antidiabetic drugs, most of which not only decrease blood sugar levels effectively but also decrease the lipid levels. Hence the current study is aimed to determine the effectiveness of oral hypoglycemic agents in dealing with associated dyslipidemia.Methods: 150 T2DM patients were divided equally into five groups depending upon the oral antidiabetic drugs they received in solo or in combination for 24 weeks, with equal number of males and females in each group. After the written consent, a detail clinical history, clinical examination, Biochemical investigations including, glycosylated haemoglobin and lipid profile, chest X-ray and ECG were done.Results: After 24 weeks of study, the mean total cholesterol and mean triglycerides decreased significantly (p <0.05 to p <0.01) with monotherapy of metformin and teneligliptin as well as with combination of either metformin and glimepiride or metformin and teneligliptin. The decrease of LDL-C and VLDL-C was not statistically significant with any of the OAD drugs in solo or in combination. Similarly, HDL-C increased significantly (p <0.05) in Group I, III, IV and V; but was most effective with combination therapy. The atherogenic index of plasma also decreased (p <0.05) with metformin or its combination with either teneligliptin or glimepiride.Conclusions: Oral antidiabetic drugs are not only affordable and effective hypoglycemic agents but can also decrease serum lipids and thereby aids in the prevention and management of atherosclerosis and its complications in T2DM.
ABSTRACT
Background: Uncomplicated cataract procedures have become very easy to perform with minimal complications. Treatment of inflammation post-surgery was usually by corticosteroides. Of late, Diclofenac sodium, a non-steroid anti- inflammatory agent is being widely tested to be used instead of corticosteroids as steroids are known for their side effects. Methods: 179 patients of both genders, undergoing elective unilateral ECCE with IOL implantation were included into this study. The patients were divided into 2 groups. Group 1 consisted of 89 patients who were given diclofenac sodium and Group 2 of 90, who were treated with dexamethasone post operatively. All patients were subjected to visometric, eye biomicroscopic, ophthalmoscopic and tonometric examination before surgery and on 1st, 3rd, 7th and 14the days post-surgery. Results: By 7th day, the visual acuity was 75% in group 1 and 695 IN Group 2. Inflammation was seen in less than 8% of the cases in both the groups showing that both the drugs are equally efficient. Conclusion: As diclofenac is as good as dexamethasone, if not better, dicofenac can be used in lieu of the latter for the treatment of inflammation in uncomplicated cataract surgeries.